TCR2 Therapeutics, a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumours, has announced the expansion of its manufacturing capacity by exercising an option on a second cleanroom at ElevateBio BaseCamp.
The new cleanroom will add to the buildout of clinical and commercial supply currently underway at TCR2 Rockville, MD, facility.
The timing of the additional supply at ElevateBio BaseCamp aligns with an anticipated 2022 increase in demand from the Phase 2 clinical trial of gavo-cel for mesothelin-expressing solid tumours as well as the start of a Phase 1 clinical trial for TC-510, a mesothelin TRuC-T cell enhanced with a PD1xCD28 switch.
The long-term focus for TCR2 clinical and commercial supply remains on developing the 85,000 sqft Rockville facility as its manufacturing centre of excellence in the US. In connection with this expansion, TCR2 proposes to cease manufacturing activities at the Cell and Gene Therapy Catapult (CGT Catapult) in Stevenage, UK.
"This increase in cGMP manufacturing capacity at ElevateBio BaseCamp will ensure we are able to execute on the gavo-cel Phase 2 trial and the clinical plans for our next-generation TRuC-T cell products," said Garry Menzel, President and CEO of TCR2 Therapeutics. "We are excited by the therapeutic potential of our lead clinical therapy gavo-cel and the emerging solid tumour pipeline reviewed recently at our R&D Day. Our strategy remains focused on continuous innovation providing multiple opportunities to save the lives of cancer patients".
